Additional file 1: of Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: a clinical case and a review of the literature

Microbiology. Description of methods used to identify the microorganism isolated from blood culture, both by standard microbiology culture and by genetic analysis; minimum inhibitory concentrations (MICs) of the antibiotics used for testing. (DOCX 11 kb

Comparison of baseline characteristics of patients with and without treatment success.

<p>*Not normal distribution, median values presented, p-value calculated by Mann-Whitney test.</p><p>**Defined as any degree of <i>failure</i> resulting from acute or chronic pathology, not including low CD4.</p>†<p>Alone or as part of pancytopenia.</p

Multivariable analysis of factors possibly associated with treatment success.

<p>Multivariable analysis of factors possibly associated with treatment success.</p

Comparison of baseline characteristics and primary outcome in beta-lactam monotherapy and combination therapy groups.

<p>*Not normal distribution, median values presented, p-value calculated by Mann-Whitney test.</p><p>**Defined as any degree of <i>failure</i> resulting from acute or chronic pathology, not including low CD4.</p>†<p>Alone or as part of pancytopenia.</p

ECG registered on May 22, 2015.

<p>ECG registered on May 22, 2015.</p

ECG registered on May 15, 2015.

<p>ECG registered on May 15, 2015.</p

Additional file 3: of Ebola virus disease complicated with viral interstitial pneumonia: a case report

Person and institution involved in the organization and management of the patient

Additional file 1: of Ebola virus disease complicated with viral interstitial pneumonia: a case report

Laboratory methods

EBOV RNA trends in plasma, sputum and nasopharyngeal specimens during the first 15 days of hospitalization of the second Italian Ebola patient attending the National Institute for Infectious Diseases in Roma (INMI2).

<p>Clinical specimens from the patient were collected daily (plasma and nasopharyngeal swab) and regularly throughout hospitalization (Sputum). Arrows indicate the administration of the experimental drug Mil77 (day 3 and day 6). Dotted lines represent the hypothetical trend of those samples not available for this study. Panel A: trend of total EBOV RNA (viremia), which becomes undetectable at day 9. Panel B: trends of neg-RNA and pos-RNA in plasma, which become undetectable at day 5 and 4, respectively. Panel C: trend of total virus RNA in sputum, which becomes undetectable at day 11. Panel D: trends of neg-RNA and pos-RNA in sputum, which become undetectable at day 11 and 10, respectively. Panel E: trend of total EBOV RNA in nasopharyngeal swab. In nasopharyngeal swab the total EBOV RNA reaches undetectable levels at day 13 of hospitalization. Panel F: trends of neg-RNA and pos-RNA in nasopharyngeal swab, which become undetectable at day 10 and 6, respectively. Symbols are specified in the panels.</p

Additional file 1: of Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study

List of local Ethics Committees which approved the study. (DOC 25 kb